期刊文献+

多条溶出曲线评价缬沙坦氨氯地平片的质量 被引量:4

Evaluation of the quality of valsartan and amlodipine tablets by dissolution curve in different mediums
原文传递
导出
摘要 目的:以国外上市的缬沙坦氨氯地平片作为参比制剂,考察自研制剂和参比制剂在不同pH的溶出介质中体外溶出行为的相似性。方法:通过测定2种制剂中氨氯地平和缬沙坦的溶出曲线,采用f2相似因子对溶出曲线的相似度进行评价。结果:在不同pH的溶出介质中,自研制剂中氨氯地平和缬沙坦的溶出曲线与参比制剂比较,f2相似因子均大于50。结论:自研制剂和参比制剂在不同pH的溶出介质中的体外溶出行为相似。 OBJECTIVE To investigate the dissolution behavior similarity between the reference preparation tablets (the listed in abroad valsartan and amlodipine tablets) and selfprepared (domestic) preparation in dissolution mediums with different pH. METHODS Through determining the dissolution curve of two preparations,then f2 similarity factor was used to evaluate the similarity of dissolution curves. RESULTS In different dissolution mediums, the dissolution curves of valsartan and amlodipine from self-prepared preparation compared with reference preparation, the similar factor(f2 ) were all more than 50. CONCLUSION The dissolution behavior of self-prepared preparation and reference preparation were similar in dissolution mediums with different pH.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第9期704-707,共4页 Chinese Journal of Hospital Pharmacy
关键词 缬沙坦 氨氯地平 溶出曲线 f2相似因子 valsartan amlodipine dissolution curve f2 similarity factor
  • 相关文献

参考文献4

二级参考文献21

共引文献622

同被引文献44

  • 1谢沐风.简介日本“药品品质再评价”工程(溶出度研究系列一)[J].中国药品标准,2005,6(6):42-46. 被引量:133
  • 2刘梅亮,李茗.反相高效液相色谱法测定替米沙坦片的含量[J].实用预防医学,2007,14(4):1223-1225. 被引量:6
  • 3Mori M, Takahashi S. Pharmacological and clinical properties of AIMIX(R) combination tablets LD g> HD, fixed-dose combination of irbesartan and amlodip- ine besilate[J]. Nihon Yakurigaku Zasshi, 2013, 142 (1) : 39-46. 被引量:1
  • 4Lambers Heerspink H J, Weldegiorgis M, Inker L A,et al. Estimated GFR decline as a surrogate end point for kidney failure a post hoe analysis from the reduc- tion of end points in non-insulin-dependent diabetes with the angiotensin II antagonist losartan (RENAAL) study and irbesartan diabetic nephropathy trial (IDNT) [J]. AmJ Kidney Dis, 2014,63(2): 244-250. 被引量:1
  • 5Zhu D, Gao P, Holtbruegge W, et al. A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodip- ine 5 mg versus amlodipine 5 mg in hypertensive Asian patients[J]. J Int Med Res, 2014,42(1):52-65. 被引量:1
  • 6Bobrie G. I-combine study: assessment of efficacy and safety profile of irbesartan/amlodipine fixe&dose com- bination therapy compared with amlodipine monothera- py in hypertensive patients uncontrolled with amlodip- ine 5 mg monotherapy: a multicenter, phase UI, pro- spective, randomized, open-label with blinded-end point evaluation study[J]. Clin Ther, 2012, 34 (8) : 1705-1719. 被引量:1
  • 7Bobrie G. I-add study: assessment of efficacy and safe- ty profile of irbesartan/amlodipine fixed-dose combina- tion therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase , prospec- tive, randomized, open-label with blinded-end point e- valuation study[J]. Clin Ther, 2012, 34(8): 1720- 1734. 被引量:1
  • 8Costa P. An alternative method to the evaluation of similarity factor in dissolution testing [J]. Int J Pharm, 2001, 220(1): 77-83. 被引量:1
  • 9Berry M R, Likar M D. Statistical assessment of dis- solution and drug release profile similarity using a mod- el-dependent approach [J]. J Pharm Biomed Anal, 2007, 45(2): 194-200. 被引量:1
  • 10Shah V P,Tsong Y,Sathe P,et al. In vitro dissolution profile comparison-statistics and analysis of the similar- ity factor, f2[J]. PharmRes, 1998, 15(6): 889-896. 被引量:1

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部